Related Experiment Videos
The dopamine receptor D2 genotype is associated with hyperprolactinemia
Keith A Hansen1, Yueyi Zhang, Robert Colver
1Department of Obstetrics and Gynecology, University of South Dakota School of Medicine, Sioux Falls, South Dakota 57105, USA. kahansen@usd.edu
Fertility and Sterility
|September 20, 2005
Summary
Genetic variations in the dopamine receptor D2 (DRD2) gene may predispose individuals to hyperprolactinemia. Specifically, homozygosity for a polymorphism in exon 7 of the DRD2 gene was linked to an increased risk of this condition.
Area of Science:
- Genetics
- Endocrinology
- Molecular Biology
Background:
- Hyperprolactinemia is a condition characterized by elevated prolactin levels.
- The dopamine receptor D2 (DRD2) plays a crucial role in regulating prolactin secretion.
Purpose of the Study:
- To investigate the association between dopamine receptor D2 (DRD2) gene polymorphisms and hyperprolactinemia.
- To evaluate if specific DRD2 gene variations contribute to the development of hyperprolactinemia.
Main Methods:
- A case-control study was conducted.
- DNA was extracted from peripheral blood of patients with hyperprolactinemia and healthy controls.
- Polymerase chain reaction, single-strand conformation polymorphism, DNA sequencing, and restriction digest were used to analyze DRD2 gene polymorphisms.
Main Results:
- Two polymorphisms in exon 7 of the DRD2 gene were analyzed.
- An increased frequency of DRD2 polymorphism 1 alleles was observed in individuals with hyperprolactinemia.
- Homozygosity for polymorphism 1 in the DRD2 gene showed a significant odds ratio of 6.77 for hyperprolactinemia.
Conclusions:
- Excess homozygosity for polymorphism 1 in the DRD2 gene suggests a potential genetic predisposition to hyperprolactinemia.
- This genetic variation may influence the distribution of DRD2 isoforms on lactotrophs.
- Alternative mechanisms, such as postreceptor signaling defects or altered receptor-G protein interactions, could also contribute to hyperprolactinemia.